Trump Signs Executive Order Directing $50 Million to Psychedelic Medical Research
Washington, Saturday, 18 April 2026.
On April 18, 2026, President Trump ordered a $50 million federal push to accelerate research and patient access to psychedelic therapies, targeting severe mental illnesses and veteran PTSD.
A Shift in Federal Healthcare Strategy
On Saturday morning, President Donald Trump signed an executive order focused on medical research during a live broadcast from the White House [1][2]. Flanked by military veterans, the President outlined a newly implemented policy aimed at addressing a severe mental health crisis, noting that the directive possesses “life-changing potential” [4][6]. According to the White House, over 14 million American adults suffer from serious mental illness, with approximately 8 million currently relying on prescription medication [3]. A tragic focal point of the administration’s new directive is the veteran population, which has experienced more than 6,000 suicides annually for over two decades—a rate more than twice that of the non-veteran adult demographic [3].
Fast-Tracking Psychedelic Therapeutics
The executive order mandates significant regulatory shifts to accelerate the development of psychedelic treatments. The Department of Health and Human Services (HHS), operating through the Advanced Research Projects Agency for Health (ARPA-H), is directed to allocate at least $50 million from existing funds to support states in developing psychedelic drug programs [3][6]. This financial commitment mirrors a similar state-level initiative from last year, when Texas Governor Greg Abbott signed a bill approving $50 million for ibogaine research [6].
Fast-Tracking Psychedelic Therapeutics
A central component of the new policy is the expansion of the Food and Drug Administration’s (FDA) “Right to Try” pathway, which will now explicitly include psychedelic compounds like ibogaine for eligible, desperately ill patients [3][6]. Furthermore, the FDA is instructed to grant Commissioner’s National Priority Vouchers to appropriate psychedelic drugs that achieve Breakthrough Therapy designation [3][6]. FDA Commissioner Marty Makary emphasized the urgency of the initiative, noting that decisions regarding these drugs could materialize as early as this summer [5]. Makary described the situation as an “unmet public health need” with “potentially promising treatments” [6].
Navigating Regulatory Hurdles and Medical Risks
Implementing this directive will require navigating substantial legal and medical complexities. Currently, substances like ibogaine, LSD, and psilocybin are classified by the Drug Enforcement Administration (DEA) as Schedule I substances, placing them in the same restrictive category as heroin and ecstasy [4][6]. To address this, the executive order directs the Attorney General, in consultation with HHS, to expedite the review process for any Schedule I product that successfully completes Phase